Skip to content
10-K

Annual Report

Stoke Therapeutics, Inc. STOK

0001193125-26-108362

← back to feed
Filed
Mar 16, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 28, 2026 59.15M sh
Shares Diluted FY 2025 · Dec 31, 2025 59.22M sh
Shares Diluted FY 2025 · Dec 31, 2024 54.01M sh
Capex FY 2025 · Dec 31, 2025 $670K
Capex FY 2025 · Dec 31, 2024 $203K
Operating Cash Flow FY 2025 · Dec 31, 2025 $45.59M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$86.85M
Cash And Equivalents FY 2025 · Dec 31, 2025 $84.22M
Cash And Equivalents FY 2025 · Dec 31, 2024 $127.98M
Stockholders Equity FY 2025 · Dec 31, 2025 $352.46M
Stockholders Equity FY 2025 · Dec 31, 2024 $229.02M
Stockholders Equity FY 2025 · Dec 31, 2023 $159.57M
Current Liabilities FY 2025 · Dec 31, 2025 $57.88M
Current Liabilities FY 2025 · Dec 31, 2024 $40.06M
Total Liabilities FY 2025 · Dec 31, 2025 $65.98M
Total Liabilities FY 2025 · Dec 31, 2024 $42.53M
Current Assets FY 2025 · Dec 31, 2025 $305.7M
Current Assets FY 2025 · Dec 31, 2024 $232.76M
Total Assets FY 2025 · Dec 31, 2025 $418.43M
Total Assets FY 2025 · Dec 31, 2024 $271.56M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.12
Eps Diluted FY 2025 · Dec 31, 2024 −$1.65
Eps Basic FY 2025 · Dec 31, 2025 −$0.12
Eps Basic FY 2025 · Dec 31, 2024 −$1.65
Sga Expense FY 2025 · Dec 31, 2025 $67.09M
Sga Expense FY 2025 · Dec 31, 2024 $48.79M
Rd Expense FY 2025 · Dec 31, 2025 $137.92M
Rd Expense FY 2025 · Dec 31, 2024 $89.13M
Net Income FY 2025 · Dec 31, 2025 −$6.89M
Net Income FY 2025 · Dec 31, 2024 −$88.98M
Operating Income FY 2025 · Dec 31, 2025 −$20.59M
Operating Income FY 2025 · Dec 31, 2024 −$101.37M
Revenue FY 2025 · Dec 31, 2025 $184.42M
Revenue FY 2025 · Dec 31, 2024 $36.56M